Bristol-Myers Squibb had won a $1.2 billion judgment for infringement of its patent on a cancer treatment. But the justices left in place a Federal Circuit decision that invalidated the patent for failing to meet the Patent Act's written description requirement.
November 08, 2022 at 02:54 PM
3 minute read
The original version of this story was published on National Law Journal
An all-star team of patent litigators could not persuade the U.S. Supreme Court to revive a $1.2 billion judgment over a cancer treatment patent.
The justices denied cert in Juno Therapeutics v. Kite Pharma, leaving in place a decision of the U.S. Court of Appeals for the Federal Circuit that invalidated Juno’s and Sloan Kettering Institute for Cancer Research’s 7,446,190 patent.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
Orrick’s Joshua Rosenkranz helped Gilead Sciences successfully defend a Federal Circuit judgment of patent invalidity. (Courtesy photo)
